Ertapenem Sodium
Ertapenem Sodium structure
|
Common Name | Ertapenem Sodium | ||
|---|---|---|---|---|
| CAS Number | 153773-82-1 | Molecular Weight | 497.49700 | |
| Density | N/A | Boiling Point | 813.9ºC at 760 mmHg | |
| Molecular Formula | C22H24N3NaO7S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 446ºC | |
Use of Ertapenem SodiumErtapenem sodium is a new long-acting 1-β-methyl carbapenem antibiotic with a broad antibacterial spectrum including common aerobic and anaerobic bacteria and organisms with extended-spectrum β-lactamases. |
| Name | ertapenem sodium |
|---|---|
| Synonym | More Synonyms |
| Description | Ertapenem sodium is a new long-acting 1-β-methyl carbapenem antibiotic with a broad antibacterial spectrum including common aerobic and anaerobic bacteria and organisms with extended-spectrum β-lactamases. |
|---|---|
| Related Catalog | |
| References |
| Boiling Point | 813.9ºC at 760 mmHg |
|---|---|
| Molecular Formula | C22H24N3NaO7S |
| Molecular Weight | 497.49700 |
| Flash Point | 446ºC |
| Exact Mass | 497.12300 |
| PSA | 184.40000 |
| Vapour Pressure | 5.26E-28mmHg at 25°C |
| Storage condition | -20℃ |
| Water Solubility | Fully miscible in water. Soluble in DMSO. |
| RIDADR | NONH for all modes of transport |
|---|
|
~%
Ertapenem Sodium CAS#:153773-82-1 |
| Literature: WO2013/121279 A2, ; Page/Page column 15 ; |
![2-[(4-Nitrophenyl)methyl] (4R,5S,6S)-3-[[(3S,5S)-5-[[(3-carboxyphenyl)amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate structure](https://www.chemsrc.com/extcaspic/239/202467-70-7.png)
|
Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis.
PLoS ONE 11 , e0148142, (2016) Organ dysfunction is a major concern in sepsis pathophysiology and contributes to its high mortality rate. Neutrophil extracellular traps (NETs) have been implicated in endothelial damage and take par... |
|
|
The Effect of Radiation Dose and Variation in Neupogen® Initiation Schedule on the Mitigation of Myelosuppression during the Concomitant GI-ARS and H-ARS in a Nonhuman Primate Model of High-dose Exposure with Marrow Sparing.
Health Phys. 109 , 427-39, (2015) A nonhuman primate (NHP) model of acute high-dose, partial-body irradiation with 5% bone marrow (PBI/BM5) sparing was used to assess the effect of Neupogen® [granulocyte colony stimulating factor (G-C... |
| 2',4',6',3,4-PENTAHYDROXYDIHYDROCHALCONE |
| eriodictoyl dihydrochalcone |
| 2',4',6',3,4-PENTAHYDROXYLDIHYDROCHALCONE |
| 3-hydoxyphloretin |
| sodium,3-[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]sulfanyl]pyrrolidine-2-carbonyl]amino]benzoate |
| 3'-hydroxyphloretin |